Ignite Creation Date:
2025-12-25 @ 5:07 AM
Ignite Modification Date:
2026-01-03 @ 9:02 PM
Study NCT ID:
NCT00627627
Status:
WITHDRAWN
Last Update Posted:
2010-02-03
First Post:
2008-02-21
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Evaluate the Antitumor Activity and Safety of IPI-504 in Patients With Advanced Breast Cancer
Sponsor:
MedImmune LLC
Organization:
Study Overview
Official Title:
A Phase 2, Open-Label, Single-Arm, Multicenter, Multinational Study to Evaluate the Antitumor Activity and Safety of IPI-504, A Novel Small Molecule Inhibitor of Heat Shock Protein 90(HSP90), in Patients With Locally Advanced or Metastatic Human Epidermal Growth Factor Receptor 2-Positive(HER2+) Breast Cancer That Has Progressed Despite Prior Her2=Targeted Therapy
Status:
WITHDRAWN
Status Verified Date:
2010-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Redirect focus of the indication
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the antitumor activity following treatment with IPI-504 in patients with breast cancer.
Detailed Description:
To evaluate the antitumor activity following treatment with IPI-504 in patients with locally advanced or metastatic HER2+ breast cancer that has progressed despite prior HER2-targeted therapy.
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: